Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
説明 | CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. |
In vitro | CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923(0.01-30 μ M; 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1]. |
In vivo | CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1]. |
分子量 | 467.54 |
分子式 | C23H25N5O4S |
CAS No. | 205256-55-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (128.33 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CT52923 205256-55-9 Angiogenesis Tyrosine Kinase/Adaptors PDGFR CT 52923 CT-52923 Inhibitor inhibitor inhibit